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Recent studies on HIV infection have identified new human B-cell subsets with a potentially important impact on
anti-viral immunity. Current work highlights the occurrence of similar B-cell alterations in other viral, bacterial, and
parasitic infections, suggesting that common strategies have been developed by pathogens to counteract protective
immunity. For this review, we have selected key examples of human infections for which B-cell alterations have been
described, to highlight the similarities and differences in the immune responses to a variety of pathogens. We believe
that further comparisons between these models will lead to critical progress in the understanding of B-cell mechanisms
and will open new target avenues for therapeutic interventions.
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Introduction
To maintain the integrity of an organism constantly
challenged by pathogens, the immune system is endowed
with a variety of cell types. B-cells exert a key role in both
the innate and adaptive branches of immunity, through
the production of protective or neutralizing antibodies
(Abs), and are well suited to recognize invading pathogens
or vaccine antigens (Ags). Depending on the pathogen
and its route of entry, different B-cell subsets, follicular or
innate B-cells, develop a specific differentiation program,
namely a T-dependent (TD) or T-independent (TI) re-
sponse [1]. Follicular (FO) B-cells are specialized for
the adaptive response, and mainly recognize proteins,
whereas marginal zone (MZ) B-cells and B1 cells sup-
port the innate response to non-protein Ags. FO B-cells
populate follicles in secondary lymphoid organs, express
mono-specific B-cell receptor (BCR) and require cognate
interactions with Ag-activated CD4+ helper T-cells for
initiating TD responses. This response, though slow to
develop, generates a unique “serological memory” that
protects from further insults by similar pathogens. In
contrast, MZ B-cells reside in the spleen MZ, the sub-* Correspondence: gwenoline.borhis@inserm.fr; yolande.richard@inserm.fr
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unless otherwise stated.capsular area of lymph nodes, and the sub-epithelial area
of mucosa, where they monitor invading blood-borne and
mucosal pathogens [2-4]. MZ B-cells and B1 cells both ex-
press poly-specific, possibly self-reactive, BCR in combin-
ation with different innate-like receptors, which deliver
co-activation signals to B-cells. Once activated they rapidly
differentiate into short-lived extra-follicular plasma cells
(PC) with the help of various innate cell types [2,5]. Blood-
borne bacteria and viruses generally express TI and TD
Ags, thereby eliciting both innate and adaptive responses.
B-cells can also exert Ab-independent regulatory func-
tions through cytokine production and/or cognate inter-
actions with T-cells or myeloid cells in mice and humans
[6-8]. Human regulatory B-cells (B-regs), displaying dif-
ferent phenotypic and functional features, can improve
or dampen immune responses, depending on the patho-
logical situation. During chronic infection by hepatitis B
virus (HBV) or HIV-1, B-regs inhibit the virus-specific
CD8+ T-cell responses [9,10]. B-cells can also act as
regulators of early innate immunity to virus infection.
Through the expression of LTα1β2, B-cells—probably
innate B-cells according to their location—are mandatory
for type I interferon (IFN)-mediated survival of mice in-
fected by cytomegalovirus [11] or vesicular stomatitis virus
[12]. In these mouse models, LTα1β2-expressing B-cells
provide critical signals for type I IFN production to sub-
capsular CD169+ macrophages in the draining lymph
nodes, and for virus containment [12]. Pathogens knownentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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variation can also use B-cells as a silent reservoir, pos-
sibly favoring pathogen spread [13-15], or can alter the
phenotypes and functions of B-cells. The latter is the
theme of this review; here we provide examples of para-
sitic, bacterial, and viral infections where B-cells with
unconventional phenotypes have been identified and are
thought to modulate the efficiency of pathogen-specific
B- and T-cell immune responses.
Distinct B-cell subsets
FO B-cells in the establishment of long-lived memory
The TD Ab response relies on the production of two
kinds of effectors from FO naïve (IgDhiIgM+CD27−CD21int)
B-cells: memory B-cells (MemB) and long-lived PC, who
produce high-affinity Abs (Figure 1). This response occurs
in lymphoid tissues, where naïve B-cells are organized in
follicles in close contact with T-cell zones. Once activated
by TD antigens (mainly proteins), naïve B-cells rapidly
proliferate at the T/B border and generate PC that locally
produce low-affinity IgM within a few days [16]. Con-
comitantly activated B-cells produce germinal center (GC)
founder cells, which proliferate in the center of follicles.
These proliferating cells no longer express BCR andFigure 1 Differentiation and trafficking of innate and follicular B-cells
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saccharides or highly repetitive motifs found in viral
capsids, which cross-link the BCR. This potent BCR ac-
tivation, along with innate cell signals, elicits a rapid differ-
entiation of MZ B-cells into extra-follicular PCs [2]. Some
TI-2 Ags can transiently induce non-productive GCs that
fail to generate MemB [21]. In contrast, TI-1 Ags are more
heterogeneous; they include lipopeptides, liposaccharides,
microbial CpG DNA, viral RNA, and some viral coat pro-
teins. TI-1 Ags deliver a synergic activation to MZ B-cells
through their BCR and toll-like receptors (TLRs), which
leads to their differentiation into PC. In the absence of
TLR4, human MZ B-cells can recognize various unrelated
molecules from a broad spectrum of microbes through
binding to their TLR2/1 and TLR2/6 complexes [22].
However, prior BCR activation is required for enhancing
MZ B-cell responsiveness to TLR ligands. For ex-
ample, BCR cross-linking by protein A from Staphylo-
coccus aureus enhances TLR2-mediated proliferation,
in vitro [23].
The key role of MZ B-cells in response to microbial
Ags is strongly supported by studies in aged and very
young individuals. Incidence of invasive pneumococcal
disease increases with age, particularly in individuals that
are over 65 years old [24]. Likewise, children under 2–3
years of age are highly susceptible to bacterial infec-
tions and develop minimal long-lasting protection towards
polysaccharide pneumococcal vaccines [25,26]. This ineffi-
cient Ab response correlates with altered organization
and functions of the spleen MZ-like area or MZ B-cells
[3,27-30]. Additionally, MZ B-cells can capture and im-
port both viral particles and high molecular weight Ags
into follicles, which accelerates the initiation of the adap-
tive response against pathogens and widens the repertoire
of Ags in the GC [31]. Thus, MZ B-cells link the innate
and adaptive immune responses.Human B1-like cells
Numerous studies have aimed to identify human B1-like
cells. Recently, Griffin et al. identified human B1-like
cells as CD20+CD27+CD43+CD21loCD23− B-cells, with
75% being CD5+ [32,33]. These cells represent a small
fraction of B-cells in adult blood and typically have spon-
taneous IgM production, skewed BCR with constitutive
signaling, efficient T-cell stimulation, and an absence of
CD70 or CD69 expression after stimulation [33]. Human
B1-like cells are enriched in phosphorylcholine-specific
B-cells [32] and produce capsular polysaccharide-specific
Abs following vaccination against Streptococcus pneumonia
(Pneumo23) [34]. Along with MZ B-cells, B1-like cells are
likely involved in the TI Ab response. However, specific
changes in human B1-like cells during infection have not
yet been described.Microbial and Parasite-induced B-cell changes
Besides directly interacting with innate B-cells, microbial
pathogens frequently modify their microenvironment and
subvert the humoral response. Here, we discuss infections
by selected widespread, mortality-causing parasites re-
ported to induce or expand unconventional B-cell subsets
(Table 1).
B-cells in human Plasmodium infection
Recent studies comparing various cohorts of individuals
exposed to Plasmodium parasites, the causal agents of
malaria, have revealed important changes in blood B-cell
composition, in addition to T-cell hypo-responsiveness,
short-lived protection by specific Abs, polyclonal B-cell
activation, and an increase in total IgG during acute in-
fection [35]. Reduced numbers of circulating MZ B-cells
have been observed in children chronically exposed to
Plasmodium parasites [36] and were associated with the
well-established malaria-associated suppression of the
anti-polysaccharide Ab response [37]. In adult women
from high and low malaria-exposed countries, reduced
proportions of blood MZ B-cells were correlated with
lower levels of Plasmodium-specific plasma IgG [38].
Additionally, elevated plasma BAFF (B-cell activating fac-
tor belonging to tumor necrosis factor family) levels, re-
duced BAFF-R expression on blood B-cells, and increased
numbers of circulating CD10+ B-cells were independently
reported during controlled human malaria infection and
in acutely infected children [36,39,40]. Initially consid-
ered to be B-cell precursors mobilized into blood in re-
sponse to BAFF over-production, several observations
suggest that these CD10+ B-cells might also include
BAFF-induced CD10+ B-regs [35]: (i) in the murine
model of Babesia microti infection, a Plasmodium-related
model, IL10+ B-regs are induced that limit parasite-
specific T-cell responses through expansion of regulatory
T-cells (Treg) [41]; (ii) BAFF was shown to expand IL10
+
B-regs in healthy mice [42]; and (iii) monocytes exposed
to the soluble fraction of malaria-infected erythrocytes
in vitro strongly express BAFF and induce B-cell prolifera-
tion and IgG secretion [43].
Increased proportions of atypical (CD21loCD27−) MemB,
which conditionally express inhibitory Fc receptor-like-4
(FcRL4), are repeatedly observed during malaria infection.
In endemic areas, atypical MemB from malaria-exposed in-
dividuals express FcRL4, in combination with enhanced ex-
pression of CD19, chemokine receptors, and activation
markers [44-46]. In these individuals, both classical and
atypical MemB can produce neutralizing Plasmodium-
specific IgG [45]. However, compared with classical MemB,
atypical MemB are enriched in poly-reactive B-cells and
recognize different Plasmodium-associated Ags [45]. In-
creased proportions of atypical MemB were also observed
in women from malaria-endemic countries and correlate
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However, natural resistance to malaria in the Fulani ethnic
group is correlated with increased proportions of both PC
and activated MemB, thought to be the major source of
protective Abs [47].
Despite similarities with tissue-like MemB [48,49], atypical
MemB in malaria-exposed individuals also have features
of PC precursors and might contribute to anti-malarial
immunity, rather than to immune exhaustion as they
do in HIV-infected patients [45,50]. Atypical MemB ob-
served during the acute phase of controlled human
malaria infection are FcRL4− [40], suggesting that FcRL4
expression might be a consequence of repeated exposure
to pathogen-associated Ags. Because FcRL4 reduces BCR
signaling but enhances responsiveness to CpG [51], atyp-
ical MemB might be highly sensitive to Plasmodium-
expressed non-classical TLR9 ligands [52]. Alternatively,
atypical MemB might develop in response to different sig-
naling pathways during infections by Plasmodium and
HIV. In controlled human malaria infection, BAFF was
recently proposed as a key factor in B-cell changes [40].
Similarly, BAFF overproduction was reported in ma-
caques acutely infected with SIV [53] and in primary
HIV-infected patients [54] and was associated with
changes in B-cell subsets. The cellular origin of atypical
MemB, the mechanisms that drive their expansion, and
their capacities to release neutralizing pathogen-specific
Abs during HIV infection vs. Plasmodium infection re-
main to be determined.
B-cells in human schistosomiasis
Chronic infection with Schistosoma haematobium causes
general immune activation, T-cell hypo-responsiveness, and
impaired myeloid DC responses [55,56]. Schistosomiasis-
infected children have increased amounts of atypical and
activated MemB but decreased levels of naïve B-cells com-
pared with uninfected children, with no differences in their
resting memory or MZ B-cell frequencies. Additionally, in-
fection by schistosomes reduces tumor necrosis factor α
(TNFα) production in BCR-stimulated MemB subsets,
and this might contribute to decreased pathogen-specific
Th1 responses. Anti-schistosome treatment with prazi-
quantel restores normal proportions of memory and naïve
B-cells but only partially corrects TNFα production [57].
Two recent articles establish that blood CD1dhiCD27− and
CD24hiCD27+ B-regs are more numerous in schistosome-
infected individuals than in healthy donors. Whereas
CD1dhi B-regs overexpress IL10, increase the frequency
of IL10+ Treg, and suppress effector T-cell cytokines
(e.g., IFNγ and IL17), the CD24hi B-regs express membrane
TGFβ1 and favor expansion of Foxp3+ Treg (CD25
+Foxp3+).
Likely expanded through different mechanisms, these two
populations synergize to dampen the schistosome-specific
T-cell responses [58,59].B-cells and infection by Mycobacterium tuberculosis
Previous studies on cellular immune responses during
Mycobacterium tuberculosis infection have established that
IL17- and IL22-producing cells, CD4+ T-cells, and NK
cells are mandatory for protective immunity against
Mycobacterium [60-62]. However, B-cells are now consid-
ered key players in shaping the Mycobacterium-specific
response through cognate interactions and cytokine
production. They are a major component of lung granu-
lomas in M. tuberculosis infection and are critical for para-
site containment [63]. Human B-cells in pleural fluid and
lung ectopic follicles enhance the functional activation of
IL17 (Th17)- and IL22 (Th22)-expressing M. tuberculosis-
specific T-cells but have no influence on Th1 expansion or
IFNγ production [64]. A restricted CD1dhiCD5+ B-cell
subset inhibits Th17/22 development through cognate
interactions but not by supplying of IL10 or TGFβ.
These B-cells also accumulate in the lung ectopic folli-
cles and blood of patients with active tuberculosis. The
percentage of circulating CD1dhiCD5+ B-cells within
total B-cells inversely correlated with that of Th17 in these
patients [65]. Although M. tuberculosis lysates enhance
the suppressive functions of B-cells, it is not known which
of the pathogen-specific Ags are responsible. In sum-
mary, different B-cell subsets with enhancing or suppres-
sive functions modulate pathogen-specific T-cell responses
and pathogen containment. Additional work is needed to
identify which mechanisms (e.g., BCR, TLR2, and TLR9)
control the expansion of suppressive B-cells in patients
with different clinical manifestations. The putative contri-
butions of innate (MZ or B1-like) B-cells and ectopic
follicle B-cells to early and late Ab-driven protection,
respectively, remain to be determined. Further study of
Ab-independent B-cell functions may aid in developing
new vaccine strategies.Multitasking B-cells during Salmonella infection
Bacteremia caused by Salmonella remains a critical human
health problem, particularly in immune-compromised indi-
viduals and pregnant women. Both mouse and human
B-cells are susceptible to Salmonella infection and can
act as pathogen reservoirs, contributing to its spread
[66]. The consequences of this infection on human B-cell
physiology and disease progression are yet unknown. In
mice, B-cells act as antigen-presenting cells required for
protective T-cell responses [67]. However, more recent
data show that B-regs, with PC attributes, exert immuno-
suppressive functions during Salmonella infection by sup-
plying IL10 and/or IL35 [68]. Although the transposition
of data from mice to humans is probably premature, these
findings might offer interesting possibilities for treatment
of Salmonella infections and also increase our understand-
ing of specific B-reg expansion.
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Developing a vaccine against HIV-1 and understanding
why the neutralizing Ab response is globally inefficient
remains a challenge. Defaults in the HIV-specific Ab re-
sponse were widely thought to result from a loss in CD4+
T-cells, but recent in-depth examinations of the B-cell
population during pathogenic and non-pathogenic HIV/
SIV infection have challenged this idea. These pioneering
studies have largely contributed to change our global un-
derstanding of the role of B-cells.
B-cells during HIV/SIV infection
B-cell dysfunctions are now considered to be a central
feature of HIV infection and an important pathogenic
mechanism [69-71]. Although B-cell hyper-activation, in-
cluding centro-follicular hyperplasia, and hypergammaglo-
bulinemia, with IgG1 being the most deregulated, were
among the first symptoms described in HIV-infected pa-
tients [72-74], the role of B-cells in HIV/SIV progression
has been largely underappreciated until recently. One
extremely puzzling issue in HIV infection is the global
inefficiency of the HIV-induced Ab response. Cumulative
data reveal that circulating virus-specific Abs are detect-
able by one month of infection, whereas neutralizing Abs
are undetectable until after 3 months. Broadly neutralizing
Abs generally develop after one or two years and in only
10–30% of untreated HIV-infected patients [75]. Most
neutralizing Abs are directed against HIV gp120 or gp41
proteins or their binding sites on CD4, CCR5, or CXCR4,
and have features of poly-reactive or self-reactive Abs [76].
Along with the virus-specific Ab response, the humoral
response to non-HIVAgs is strongly impaired, resulting in
a decreased response to natural or vaccine TI and TD Ags
as early as during the acute phase of infection [71,77]. To-
gether, these data suggest that both the innate (TI) and
virus-specific (TD) arms of the Ab response are impaired
during HIV infection.
Chronically HIV-infected patients are reported to ex-
perience a loss in circulating MZ-like B-cells, associated
with an impaired response to pneumococcal Ags [77,78].
Similarly, following infection, primary SIV-infected ma-
caques have reduced proportions of MZ B-cells, not only
in blood but also in spleen and peripheral lymph nodes
[79]. Additionally, increases in circulating IgM and IgG
levels and in PC numbers were observed in the spleen
MZ of these animals from two weeks post-infection.
Thus, virus-activated MZ B-cells likely differentiate into
PC. This idea is consistent with a report showing that
gp120-activated MZ-like B-cells rapidly produce IgG
and IgA [80]. However, the most striking effect of HIV
infection occurs within the MemB pool. Resting MemB
constitute the predominant fraction of blood MemB in
healthy donors, with low percentages of activated and
atypical MemB [81]. In contrast, there is a paucity ofresting MemB while both activated and atypical MemB
are over-represented in the blood of chronically HIV-
infected patients [70]. A similar decrease in resting
MemB has been reported during pathogenic SIV infec-
tion [53,79,82], and this loss is concomitant with BAFF
overproduction during the acute phase [53].
In chronically HIV-infected patients, atypical MemB
are exhausted B-cells that express FcRL4 and other in-
hibitory receptors and are unresponsive to BCR trigger-
ing [50]. These cells, however, are highly responsive to
TLR9 ligands and, therefore, could play a role in Ab or
cytokine production. FcRL4 expression appears to pro-
tect MemB from the deleterious effects of chronic infec-
tion or inflammation [51]. Within the atypical MemB
pool, HIV-specific Abs are enriched, and their production
might be further enhanced by treatment with short-
interfering RNA targeting FcRL4 or SIGLEC-6 [50,83].
FcRL4 expression and TGFβ1 production are induced
by the binding of recombinant gp120 to the α4β7 integ-
rin expressed by naïve B-cells [84]. Co-culture of B-cells
with CD4+ T-cells from HIV-infected donors similarly up-
regulates B-cell FcRL4 expression. Interactions between
gp120 and α4β7 also reduce B-cell proliferative responses
and CD80 expression [84]. The latter is consistent with our
previous data showing decreased CD80, but not CD86,
expression in GC B-cells from chronically HIV-infected
patients [85]. Thus HIV-1 might impair both the BCR
responses and co-stimulation abilities of B-cells, at least
during the chronic phase of infection. Moreover, X4
gp120 proteins strongly reduce B-cell chemotaxis to not
only CXCL12 but also to CCL20 and CCL21 by cross-
desensitization of CCR6 and CCR7. Additionally, they
induce CD62L cleavage and enhance MemB CD95 ex-
pression [86]. In summary, HIV has developed various
envelope-based strategies to subvert B-cell responses,
survival, and trafficking.
A key checkpoint for adaptive B-cell responses is the
GC reaction leading to the generation of MemB and
long-lived PC precursors. Although GC hyperplasia during
pathogenic HIV/SIV infection was described long ago
[85,87,88], the precise impact of the virus on GC B-cells re-
mains elusive. We previously described the well-conserved
organization and polarization of GC from the in splenic,
nodular and intestinal follicles during primary SIV infec-
tion [53,79]. Levesque et al. observed GC fragmentation in
primary HIV-infected patients [89], but generally GC invo-
lution is more frequent during the chronic and advanced
phases of HIV infection when CXCR4 variants are present
[85]. Similarly, early GC disruption occurs after SIV infec-
tion of Indian rhesus macaques, a model of rapid disease
progression, [90] but not in the more typical models using
cynomolgus or Chinese rhesus macaques [53,91].
Recent progress on the characterization of TFH cells
has clarified some points. First, circulating or nodular
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more strongly than other CD4+ T-cells, but survive lon-
ger despite continuous exposure to virus [53,92-94].
Second, during the acute phase of infection TFH cells
are moderately expanded in most individuals, with a
correlation between tissue viral load and percentages of
TFH cells [95]. In contrast, chronically HIV-infected in-
dividuals and SIV-infected animals have strong inter-
individual variation in their percentages of TFH cells
[92-94]. However, conflicting results have been reported
regarding the correlation between viral load and pro-
portions of TFH during the chronic phase of infection
[92,93]. Based on the proportions of CD4+CD45RO+ or
CD4+PD1hi T cells in GC, it was possible to correlate
TFH and GC hyperplasia in SIV-infected macaques and
in the lymph nodes of chronically HIV-infected patients
by in situ analysis [53,91,93]. In summary, during HIV/
SIV infection TFH cells are expanded and GCs are correctly
polarized but the virus-specific response is delayed, and
when it occurs, it provides relatively inefficient protection.
These paradoxical findings suggest that more subtle
dysfunctions of GC B-cells, TFH cells, or of their dialog
occur during HIV infection and impair either the gener-
ation (within GC) or the survival and trafficking of effector
B-cells (MemB or PC). The production of MemB with
“alternate” phenotypes is consistent with a dysfunction
of GC B-cells but might coexist with other impairments.
Given that the virus is able to replicate within TFH cells,
gp120, Tat, and Nef proteins might be locally over-
produced and interfere with the GC reaction. Indeed, Nef
was shown to affect Ig class switching [96], and soluble
Tat selectively increases CD40-mediated proliferation
of GC B-cells [97]. In-depth phenotypic, molecular, and
functional analyses of B-cell and T-cell subsets within
GC and at the follicular border during the priming phase
are required for a better understanding of the HIV-
induced defaults that cause inappropriate Ab responses.
In this already complex situation, a new B-cell subset
with regulatory functions has been recently identified. This
population with a CD19+CD38hiCD24hiPD-L1+ (CD27−)
phenotype spontaneously secretes IL10 and inhibits CD8+
T-cell proliferation and the HIV-specific cytotoxic response
in antiretroviral-treated or untreated HIV-infected patients
[9]. Besides IL10, PD-L1/PD1 interactions are assumed to
critically contribute to CD8+ T-cell exhaustion. Patients
with advanced HIV-disease also have increased proportions
of circulating CD10+ immature-transitional B-cells [98].
Because IL7 and BAFF plasma levels were elevated in these
patients [98,99], bone marrow dysfunctions and/or lym-
phopenia are thought to induce CD10+ B-cell mobilization
into the periphery. Moreover, our data suggest that
CD10+CD38+SIgD+ B-cells, which are more numerous
in HIV-infected patients with a high Epstein-Barr virus
(EBV) viral load and a strong depletion of resting MemB,might constitute an alternate EBV reservoir [100]. Because
EBV+ B-cell lymphomas occur with a higher incidence in
HIV-infected individuals than in the general population
[101], the contribution of these CD10+ B-cells should be
further examined.B-cells during hepatitis infection
Similarly to infection with HIV, infection with HBV or
hepatitis C virus (HCV) is associated with polyclonal B-cell
activation. When produced during the acute phase of in-
fection, neutralizing Abs are associated with viral clearance
[102]; unfortunately they frequently develop only during
the chronic phase [103]. In chronically HCV-infected
patients, B-cell dysfunction is reflected by IgG1 restriction,
with low-titer and delayed-onset Ab responses [104]. Loss
in resting MemB was associated with increased propor-
tions of atypical MemB in HCV-infected patients, regard-
less of cirrhosis or hepatocellular carcinoma. This increase
is likely present as early as during the acute phase of HCV
infection. These atypical MemB are hypo-proliferative in
response to CD40 or BCR stimulation but produce high
amounts of IgG [105,106]. Increased MemB IgG produc-
tion was observed in chronically HBV- and HCV-infected
patients [107]. HCV is the only hepatitis infection model
in which B-cell infection by particular virus quasi-species
has been strongly demonstrated [108] and shown to be
important for disease outcome [109]. In chronically HCV-
infected patients, elevated levels of serum BAFF have been
associated with autoimmunity [110]
HBV core Ag has the unique capacity to stimulate BCR
in a non-Ag specific manner leading to sustained B-
cell activation in chronically HBV-infected patients
[107,111]. Although an extensive phenotypic and func-
tional analysis of B-cells in HBV-infected patients is
still lacking, Das et al. recently identified a unique subset
of CD38hiCD24hiCD27− B-regs, whose frequency corre-
lates with spontaneous flares of liver disease, viral load,
and serum IL10 levels. This B-cell population inhibits
virus-specific CD8+ T-cell responses, but dampens liver
inflammation through IL10 production [10].Conclusion
This review highlights how infections by pathogens with
strongly different physiopathology lead to similar changes
in B-cell phenotypes but can differently alter protective re-
sponses. As previously shown in HIV-1-infected patients,
these pathogens preferentially impair the MemB compart-
ment and frequently induce B-reg subsets that inhibit
either CD4+ (parasites) or CD8+ (virus) T-cell responses.
Remaining questions include the origin (MZ or FO B-cells),
the mechanisms of induction, and the functional abilities of
atypical MemB in various infections. Understanding the
physiopathological role of B-cells during infection is
Borhis and Richard BMC Immunology  (2015) 16:15 Page 8 of 10important, and advances in one model of infection
should benefit others.
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